Modality
Cell Therapy
MOA
Cl18.2
Target
CD19
Pathway
DDR
MelanomaASMyelofibrosis
Development Pipeline
Preclinical
~Aug 2020
→ ~Nov 2021
Phase 1
Feb 2022
→ Apr 2027
Phase 1Current
NCT06818538
439 pts·AS
2022-02→2027-04·Recruiting
NCT07615087
1,187 pts·AS
2024-09→TBD·Recruiting
1,626 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-202mo awayEnrollment Complete· Melanoma
2027-04-261.1y awayInterim· AS
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Recruit…
P1
Recruit…
Catalysts
Enrollment Complete
2026-05-20 · 2mo away
Melanoma
Interim
2027-04-26 · 1.1y away
AS
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06818538 | Phase 1 | AS | Recruiting | 439 | Safety |
| NCT07615087 | Phase 1 | AS | Recruiting | 1187 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| ELV-1411 | Enliven | NDA/BLA | HER2 |